---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-058628"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2022-05-11T23:59:59+00:00"
generated_at: "2026-06-25T21:14:14.144158+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Pharma Q1 net loss $2.9M; cash $16.7M; NXP800 Phase 1 dose escalation ongoing

## Summary
- Net loss of $2.9M for Q1 2022, including $0.2M non-cash expense.
- Cash, cash equivalents and short-term investments of $16.7M at March 31, 2022, up from $5.7M at Dec 31, 2021 due to IPO.
- R&D expenses $1.8M; G&A expenses $1.1M for the quarter.
- NXP800 Phase 1 dose escalation portion ongoing; presented at 2022 AACR 'New Drugs on the Horizon'.
- Completed IPO in Feb 2022 raising $16M gross proceeds.

## SEC filing metadata
- accession: 0001104659-22-058628
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2022-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465922058628/0001104659-22-058628-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465922058628/tm2214978d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-058628
- JSON: https://secwatch.observer/filing/0001104659-22-058628.json
- Plain text: https://secwatch.observer/filing/0001104659-22-058628.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.